Meeting
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
Authors
Xing Zhang
Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China
Xing Zhang , Xizhi Wen , Guojuan Chen , Shan Zeng , Lichuang Men , Hengbang Wang , Shulan He , Yuxiang Ma , QiuZhong Pan , Yang Zhang , Ruiqing Peng , Desheng Weng , Wenqin Liu , Li Zhang , ZHIYAN LIANG , Dajun Yang , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
CTR20170975
Citation
J Clin Oncol 38: 2020 (suppl; abstr 11542)
DOI
10.1200/JCO.2020.38.15_suppl.11542
Abstract #
11542
Poster Bd #
430
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.
First Author: Xing Zhang
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2022 ASCO Annual Meeting
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
First Author: Meredith McKean